Australia's Zelira jumps on launching CBD-based acne treatments

Zelira Therapeutics

23/09/2021 04:06

** Shares of Zelira Therapeutics Ltd  ZLD.AX  climb as much
as 13.2% to A$0.043, their sharpest intraday pct gain since Nov.
23, 2020
    ** ZLD trades at its highest since Aug. 16
    ** Biopharma co's dermatology unit launches its first
product brand targetting acne (https://bit.ly/3lJqhlW)
 
    ** The product, RAF FIVE, consists of five acne treatments
incorporating cannabidiol (CBD), an essential component of
medical marijuana
    ** Co's dermatology unit developing other products for
launch in 2022 targetting anti-ageing, sexual health and skin
conditions such as psoriasis
    ** About 3.1 mln shares change hands, 2.4x the 30-day
average volume of 1.3 mln
    ** Stock down 58.7 % so far this year

 (Reporting by Aneetta Thomas)
 ((Aneetta.Thomas@thomsonreuters.com;))